Swiss Life Asset Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Swiss Life Asset Management’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$343K	Buy	1,167 +109	+10%	+$30.9K	﹤0.01%	1172
2026 Q1	$295K	Buy	1,058 +186	+21%	+$53.6K	﹤0.01%	1128
2025 Q4	$264K	Hold	872	–	–	﹤0.01%	1098
2025 Q3	$245K	Sell	872 -369	-30%	-$100K	﹤0.01%	1018
2025 Q2	$299K	Sell	1,241 -646	-34%	-$153K	﹤0.01%	724
2025 Q1	$460K	Buy	1,887 +371	+24%	+$112K	﹤0.01%	659
2024 Q4	$497K	Buy	1,516 +832	+122%	+$282K	﹤0.01%	658
2024 Q3	$229K	Buy	+684	New	+$217K	﹤0.01%	618
2022 Q2	–	Sell	-433	Closed	-$243K	–	640
2022 Q1	$243K	Buy	+433	New	+$261K	﹤0.01%	565
2021 Q4	–	Sell	-3,461	Closed	-$2.58M	–	546
2021 Q3	$2.58M	Sell	3,461 -268	-7%	-$201K	0.04%	392
2021 Q2	$5.32M	Sell	3,729 -1,010	-21%	-$615K	0.05%	313
2021 Q1	$2.71M	Buy	4,739 +3,062	+183%	+$1.81M	0.04%	393
2020 Q4	$978K	Sell	1,677 -57	-3%	-$32.5K	0.01%	442
2020 Q3	$894K	Sell	1,734 -7,666	-82%	-$3.88M	0.01%	379
2020 Q2	$4.24M	Buy	+9,400	New	+$4.15M	0.07%	197

Other funds holding BIO

First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return

Swiss Life Asset Management's BIO Position: Q2 2026 in Review

Swiss Life Asset Management increased its Bio-Rad Laboratories Class A (BIO) stake by 10% in Q2 2026, buying an estimated $30.9K and bringing the position to 1,167 shares worth $343K. The position accounts for ﹤0.01% of the portfolio, ranked #1172.

Swiss Life Asset Management first reported a position in BIO in Q2 2020 and has held it in 15 quarters since. The position peaked at $5.32M in Q2 2021. 253 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

Swiss Life Asset Management held 1,167 shares of Bio-Rad Laboratories Class A worth $343K as of Q2 2026.
Swiss Life Asset Management bought 109 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $30.9K.
Bio-Rad Laboratories Class A made up ﹤0.01% of Swiss Life Asset Management's portfolio in Q2 2026, its #1172 holding.
Swiss Life Asset Management first reported a position in Bio-Rad Laboratories Class A in Q2 2020 and has held it in 15 quarters since.
Swiss Life Asset Management's Bio-Rad Laboratories Class A position peaked at $5.32M in Q2 2021.
253 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.